RSABE - ANVISA [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2018-09-22 16:11 (2041 d 14:19 ago) – Posting: # 19298
Views: 2,102

Dear Maitri,

❝ Can any one comment on acceptability of Reference Scale Bioequivalence Approach for ANVISA ( Regulatory agency of Brazil) for highly variable drugs? Do they accept RSABE study design for Highly variable drug compunds?


Have you ever discovered the search field in the upper right corner of the forum?

Use it and you will find some threads dealing with the ANVISA specifications for scaled ABE. E.g. this one.

What do you think: If they have specifications for scaled ABE, do they accept studies using that approach?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,656 registered users;
104 visitors (0 registered, 104 guests [including 2 identified bots]).
Forum time: 06:31 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5